Chinese state-owned firm signs deal with Pfizer to supply Covid-19 pill


68c40803-064b-47ef-9e73-9d07e6f183d9_98dc2753

Pfizer’s Covid-19 pill is one step closer to clinical use in China, with state-owned China Meheco Corp securing a deal with Pfizer to commercialise the drug within the year.

The Chinese company had signed a contract with Pfizer and was authorised to supply Paxlovid in China during the 2022 agreement period, China Meheco said in a statement on Wednesday night.

Get 30% off with our ads free Premium Plan!

Monthly Plan

RM13.90/month
RM9.73 only

Billed as RM9.73 for the 1st month then RM13.90 thereafters.

Annual Plan

RM12.33/month
RM8.63/month

Billed as RM103.60 for the 1st year then RM148 thereafters.

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!

SCMO , China , Covid-19 , Pills , Pfizer

   

Next In Aseanplus News

Megawati, Jokowi feud intensifies after his dismissal
Fired SingPost CEO, CFO to contest employment termination, say move ‘without merits and unfair’
Upper Thailand remains very cold, with a minimum temperature of 12�C
FBM KLCI edges higher at midday, banking stocks lead
Call for collaboration in preserving South-East Asian crafts
South Korean team develops ‘Iron Man’ robot that helps paraplegics walk
Organised crime trial of 22 GISB leaders transferred to Shah Alam High Court
Two fishermen arrive home after six-day ordeal in open seas
Airbus, Rolls-Royce step in to resolve Malaysia Airlines' grounded A330neo
Sabah to host inaugural Asean tourism networking event in June

Others Also Read